Drug intelligence / Profile preview

GM101

Development stage: Unknown
Lead developer: Shanghai Genemagic Biosciences
Administration: Intracranial

Overview

GM101 is a biological injection developed by Genemagic Biosciences Co., Ltd. It is being investigated for the treatment of mid-to-late stage Parkinson's disease, with administration involving neurosurgical delivery to the putamen.

Other names: GM101注射液

Targets

CXADR (Coxsackievirus and adenovirus receptor)

Beyond the preview

Go deeper on GM101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GM101.

Explore the full profile